New drug cocktail targets Hard-to-Treat HER2 cancers
NCT ID NCT04704661
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 37 times
Summary
This early-phase trial is testing whether combining the targeted drug trastuzumab deruxtecan (DS-8201a) with an experimental pill called ceralasertib can safely treat advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the safest dose in 51 patients with various cancers; second, comparing the combo against DS-8201a alone in colorectal and gastroesophageal cancers. The goal is to see if blocking a DNA repair enzyme with ceralasertib makes the chemotherapy more effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112, United States
-
Los Angeles General Medical Center
Los Angeles, California, 90033, United States
-
Memorial Hospital East
Shiloh, Illinois, 62269, United States
-
NYP/Weill Cornell Medical Center
New York, New York, 10065, United States
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
-
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California, 92612, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
UT MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, 75390, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0565, United States
-
University of Texas at Austin
Austin, Texas, 78712, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab deruxtecan (DS-8201a) and ceralasertib (AZD6738)
What this could lead to
If successful, this could lead to a new combination treatment option for advanced HER2-positive cancers that have stopped responding to standard therapy.
What could go wrong
This is a very early Phase 1 trial with only 51 participants, so safety and dosing are still being figured out. The combination may cause significant side effects or fail to shrink tumors in many patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.